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Abstract 
Background: Recent recommendations suggest that in patients with severe aortic stenosis 
undergoing transcatheter aortic valve implantation (TAVI) and co-existent significant 
coronary artery disease (CAD), the latter should be treated before the index procedure. 
However, the evidence basis for such an approach remains limited. We performed a 
systematic review and meta-analysis to study the clinical outcomes of patients with CAD and 
underwent revascularization versus without revascularization prior to TAVI.  
Methods and Results: We conducted a search of MEDLINE and EMBASE to identify 
studies evaluating patients who underwent TAVI with/without percutaneous coronary 
intervention (PCI). Random-effects meta-analyses with the inverse variance method were 
used to estimate the rate and risk of adverse outcomes. Nine studies involving 3,858 
participants were included in the meta-analysis. Patients who underwent revascularization 
with PCI had a higher rate of major vascular complications (odd ratio [OR]: 1.79, 95% 
confidence interval [CI]: 1.31-2.45, P=0.0002) and an increased 30-day mortality (OR: 1.39, 
95%CI: 1.08-1.79, P=0.010). No statistically significant differences in terms of 1-year 
mortality (OR: 1.03, 95%CI: 0.79-1.34, P=0.83), cardiovascular mortality (OR: 1.03, 95%CI: 
0.37-2.87, P=0.96), myocardial infarction (OR: 0.86, 95%CI: 0.14-5.17, P=0.87), acute 
kidney injury (OR: 0.89, 95%CI: 0.47-1.71, P=0.73) or stroke (OR: 1.06, 95%CI: 0.39-2.86, 
P=0.90). The timing, same-setting versus elective did not negatively influence outcomes. 
Conclusions: Our analysis suggests that revascularization before TAVI confers no clinical 
advantage with respect to several patient-important clinical outcomes, and may be associated 
with an increased risk of major vascular complications and 30-day mortality.  
 
 
Keywords: transcatheter aortic valve implantation; percutaneous coronary intervention; 
coronary artery disease  
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INTRODUCTION 
Coronary artery disease (CAD) often co-exists in patients with severe aortic stenosis,1, 2 
and current American and European guidelines recommend combined coronary artery bypass 
grafting (CABG) at the time of surgical aortic valve replacement (SAVR).3, 4 Concomitant 
CABG and SAVR is associated with worse postoperative outcomes, although no negative 
impact on operative and 1-year mortality.5, 6 Nevertheless, the role of revascularization on 
long-term morbidity and mortality is still not clear in octogenarians.7  
The prevalence of CAD in the population undergoing transcatheter aortic valve 
implantation (TAVI) is higher than SAVR and, depending on the definition, the presence of 
significant CAD ranges from 50 to 75%.8-12 Notably, randomized clinical trials that led to the 
approval of TAVI devices in United States required revascularization of significant CAD 
affecting main epicardial vessels within 30 days of TAVI. In this context, it has been 
recommended to perform percutaneous coronary intervention (PCI) or a hybrid procedure to 
revascularize patients with significant CAD.13-15 Favourable outcomes associated with prior-
TAVI PCI have been reported in single-centre studies with relatively small sample sizes, 
although these were often underpowered for the endpoints studied and were also subject to 
significant selection biases. In addition, data on whether revascularization should be 
performed before or in the same-setting is still scant. Hence, the aim of this report was to 
perform a systematic review and meta-analysis to assess the evidence basis and clinical 
outcomes associated with TAVI procedures performed with and without revascularization of 
co-existent CAD with PCI. 
METHODS 
Search Strategy 
We conducted a search of MEDLINE, EMBASE, Google Scholar, Science Direct, Web 
of Science, and conference abstracts, from conception to September 2016 using OvidSP 
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(Ovid Technologies). The terms used were: ((transcatheter aortic valve implantation OR 
transfemoral aortic valve implantation OR transapical aortic valve implantation OR trans-
subclavian aortic valve implantation OR TAVI OR transcatheter aortic valve replacement OR 
TAVR) AND (percutaneous coronary intervention OR PCI OR coronary angioplasty)). 
Institutional review board approval and patient consent were not required as only publication 
level data published in the public arena was analyzed. 
Study selection 
The abstract and titles yielded by the search were screened by two independent 
investigators (RAK and CSK) against the inclusion criteria. Additional studies were retrieved 
by checking the bibliography of included studies and relevant reviews. The full reports of 
potentially relevant studies were retrieved, and data was independently extracted on study 
design, participant characteristics, treatment groups, outcome events, follow-up and results. 
Any discrepancies between reviewers were resolved by discussion after consulting a third 
investigator (RB). 
Eligibility Criteria 
We only included studies published in English that evaluated patients with underlying 
CAD that underwent PCI as a revascularization strategy prior or concomitant with TAVI 
versus no revascularization. In terms of outcomes, studies included must have evaluated one 
or more of the following events: 30-day and 1-year mortality, myocardial infarction (MI), 
vascular complications, bleeding, neurological events (stroke or transient ischemic attack 
[TIA]), acute kidney injury (AKI). Endpoints were reported, when available, in accordance to 
Valve Academic Research Consortium-2 (VARC) definitions.16 The reporting of outcomes 
had to include either crude events in each group or any risk/odds estimate (risk-ratio, odds-
ratio [OR]) with 95% confidence intervals (CI). There was no restriction based on the design 
of the study or duration of follow-up. We excluded isolated case reports/case series (≤3 
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patients), reviews and editorial comments on the subject. When duplicate reports of the same 
study were identified, only the report with the most complete dataset and detailed 
methodology description was included. A flow diagram is provided following the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA),17 Figure 1. 
Quality and risk of bias assessment 
To assess the quality of included cohort studies, we employed the Newcastle-Ottawa 
Scale.18 The outcomes of interest and follow-up were also extracted on a pre-formatted table. 
Disagreements were resolved by consensus after consultation with RB. Risk of bias was 
assessed by considering the ascertainment of treatment groups, ascertainment of outcomes, 
loss to follow-up and consideration of potential confounders in the data analysis. 
Data Analysis   
We used RevMan (Review Manager version 5.1.7; Nordic Cochrane Centre, 
København, Denmark) to perform random-effects meta-analysis using the Mantel-Haenszel 
method to determine pooled OR for dichotomous data with regards to post-TAVI outcomes 
with PCI revascularization compared without PCI. To ensure a meta-analysis with clinically 
transferable results, we only included studies where the methodology or dataset of which 
permitted adjudication of CAD prevalence in the TAVI alone group. The Cochrane Q-
statistic (I2) was used to assess the consistency among studies with I2<25% considered low, I2 
25-50% moderate, and I2>75% high statistical heterogeneity.19 Where there was insufficient 
data or studies for meta-analysis, we pooled the studies using weighted average or performed 
narrative synthesis of studies that were too heterogeneous to pool. Sensitivity analysis were 
performed to assess the potential influence of any estimates on treatment effect or association 
that are derived from the mean by excluding the study considered as an outlier20 and, to 
further assess for potential differences between random-effects and fixed-effects models and 
excluding studies where one of the treatment arms had no events.  Subgroup analyses were 
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performed to determine whether studies reporting a population with 100% of the patients 
with CAD versus those with >50% (but <100%) of the subjects presenting with CAD 
influenced the treatment effect. Meta-regression was performed to further investigate 
potential source of clinical heterogeneity21 and determine the influence of CAD on outcomes. 
The metareg function (STATA 14.0, Stat Corp.) was used to undertake meta-regression with 
log-risk estimates and the standard error determined from 95%CIs for the log-risk estimates. 
Prevalence of CAD was calculated by averaging the percentage of patients with CAD in 
TAVI-PCI and TAVI alone groups. Two-sided P values of 0.05 were considered statistically 
significant. 
RESULTS 
Study population 
A total of 24 observational studies9-12, 22-41 including 7,457 participants met the 
inclusion criteria for the systematic review; among these, 9 studies9, 10, 12, 25, 31, 32, 35, 37, 40 met 
criteria for the meta-analysis evaluating 3,858 participants (Figure 1) of which, 983 patients 
underwent TAVI with PCI revascularization strategy. The mean age was 85.3 years and 
48.4% were female from 14 studies that reported both age and gender.9-12, 23, 26, 28, 31-33, 35, 36, 39, 
40 Anatomically significant CAD was inconsistently defined and included at least ≥50% 
diameter stenosis in 7 studies,9, 10, 12, 28, 29, 34, 38 >70% stenosis in 5 studies,11, 24, 31, 36, 37 and 
>90% stenosis in 1 study.35 A total of 4 studies,11, 35, 37, 38 defined >50% stenosis when located 
in the left main. None of the studies reported on the use of functional assessment for CAD 
significance. Further details on study design and participants baseline characteristics are 
presented in Tables 1 and 2. 
Quality assessment 
 Ascertainment of outcomes varied from medical record reviews to prospective 
evaluation with adjudicated clinical end-points. All studies contained no major loss to follow-
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up, and the overall quality rate was average. Follow-up of patients varied from in-hospital 
outcomes, clinical visits, and telephone calls up to 4-year from the date of implant. Whilst 
follow-up amongst studies was inconsistent, the commonest time-points were at 30 days and 
1 year. The Newcastle-Ottawa Quality Assessment is presented Table 3.  
In-hospital, 30-day and long-term outcome with PCI versus TAVI alone 
 Device type, access site, procedure-related outcomes and follow-up assessment for all 
included studies reporting crude rate of events are summarized in Table 4. Crude outcomes 
per revascularization-PCI versus without revascularization strategies are shown in Table 5. 
The crude all-cause 30-day mortality was reported in 18 studies9-12, 23, 25, 26, 28, 31-37, 39-41 and 
occurred in 7.2% (401/5,574) of patients; crude cardiovascular 30-day mortality was reported 
in 5 studies10, 12, 28, 31, 32 and occurred in 5.0% (52/1,046) of patients. At 30-day, the crude 
incidence of MI was reported in 10 studies10-12, 25, 28, 31-33, 35, 39 and occurred in 1.7% 
(33/1,903) of patients, major or life-threatening bleeding in 12 studies10-12, 28, 31-36, 39-41 and 
occurred in 13.8% (608/4,403) of patients, AKI in 14 studies10, 12, 22, 23, 28, 31-36, 39-41 and 
occurred in 5.6% (263/4,671) of patients.  
Meta-analyses evaluating outcomes showed that patients who underwent 
revascularization were more likely to experience major vascular complications (OR: 1.86, 
95%CI: 1.33-2.60, P=0.0003, I2=0%) and an increased 30-day mortality (OR: 1.42, 95%CI: 
1.08-1.87, P=0.01, I2=0%). There were no significant differences in point estimates for 30-
day MI (OR: 0.86, 95%CI: 0.14-5.17), major or life threatening bleeding (OR: 0.87, 95%CI: 
0.58-1.29), AKI and/or need for hemodialysis (OR: 0.89, 95%CI: 0.47-1.71), stroke/TIA 
(OR: 1.06, 95%CI: 0.39-2.86), combined safety endpoint (OR: 0.84, 95%CI: 0.55-1.27), 
Figure 2.  
A total of 9 studies reported on 1-year9, 27, 28, 32, 35, 37-39, 41 and 2 studies on 2-year 
mortality32, 35 rates. The crude incidence of death at 1 year was 21% (607/2,883), and at 2 
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years was 57.5% (258/449) of patients. Meta-analyses evaluating 1-year mortality between 
pre-TAVI PCI versus without revascularization strategies showed no significant differences 
in point estimate (OR: 1.03, 95%CI: 0.79-1.34), Figure 2. 
Notably, whilst most of the included studies were small and reported neutral results, 
Singh et al.40 presented a large sample-size and reported adverse outcomes with PCI. In 
addition, the 95%CI of all the studies except for Singh’s overlap 1 (Figure 2), and the 95%CI 
of the overall effect estimate do not overlap 1. Hence, sensitivity analysis excluding this 
study showed a decrease in the effect estimates for 30-day mortality (OR: 1.15, 95%CI: 0.69-
1.92, P=0.59; heterogeneity P=0.62, I2=0%) and major vascular complications (OR: 1.38, 
95%CI: 0.61-3.10, P=0.44; heterogeneity P=0.90, I2=0%), though widening the confidence 
intervals in the latter. The remaining sensitivity-analysed outcomes remained unchanged, 
Figure 3. 
Pre-procedural versus same-setting revascularization 
Revascularization PCI was performed either concomitantly with TAVI or a priori in 12 
studies.10, 11, 22, 23, 25, 27, 29, 33, 34, 38-40 Eight studies exclusively revascularized patients prior to 
TAVI,9, 12, 24, 28, 31, 36, 37, 41 one study in the same-setting35 and one study reported both 
strategies.10 Five studies reported outcomes based on PCI-timing,10, 22, 23, 33, 36 and those who 
underwent prior-PCI varied from same-setting12 to 6 months41 prior to TAVI. 
Meta-analyses evaluating a priori PCI versus concomitant revascularization strategies 
showed comparable point estimates for 30-day mortality (OR: 1.23, 95%CI: 0.46-3.29), 
major or life threatening bleeding (OR: 0.50, 95%CI: 0.20-1.25), or major vascular 
complications (OR: 0.32, 95%CI: 0.05-1.94), Figure 4. 
Co-existing coronary artery disease  
The prevalence of co-existing CAD was reported in both revascularised and non-
revascularised groups in 9 studies,9, 10, 12, 25, 31, 32, 35, 37, 40 and varied from 51.4% to 100%. 
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Therefore, we conducted a subgroup analysis for clinical outcomes comparing studies 
reporting a population with 100% of patients with CAD versus those with >50% (but <100%) 
of the subjects presenting with CAD.  
Subgroup analysis including studies in which the prevalence of CAD was 100%, the 
OR for 30-day mortality among patients that underwent PCI was 0.80 (95%CI: 0.28-2.27), 
whereas in studies where the prevalence of CAD was >50% (but <100%), patients who 
received PCI died more often (OR: 1.49, 95%CI: 1.12-1.98, P=0.006; heterogeneity P=0.45, 
I2=0%). The overall difference showed statistically significant effect estimates (OR: 1.42, 
95%CI: 1.08-1.87, P=0.01; heterogeneity P=0.63, I2=0%) without significant interaction 
(P=0.65, I2=20%). No significant differences in effect estimates were observed in terms of 
cardiovascular (OR: 1.03, 95%CI: 0.37-2.87) and 1-year (OR: 1.03, 95%CI: 0.79-1.34) 
mortality rates. Similar effect estimates were found between the two strategies in the 
remaining analyzed variables (Figure 5).  
Sensitivity analysis comparing random- versus fixed-effects model as well as excluding 
studies with no events in one of the treatment arms is shown in Table 6. The results suggest 
no differences in effect estimates between the two models or after excluding studies with no 
events in one of the treatment arms. Meta-regression analysis was conducted to further 
investigate potential source of clinical heterogeneity based upon the prevalence of CAD.  The 
results rule-out a strong magnitude of the effect to influence any of the analyzed outcomes 
(Table 7). 
DISCUSSION 
The results of this meta-analysis of 9 observational studies including 3,858 patients 
show that PCI-revascularization before (prior to and concomitant) TAVI may be associated 
with an increased risk of major vascular complications and 30-day mortality, although by one 
year this association is no longer present. In addition, comparing TAVI with and without 
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revascularization, there were no significant differences in rates of MI, bleeding, 
AKI/hemodialysis or cerebrovascular accidents at 30 days. We find that the evidence basis 
consists of poor quality of the studies confounded by selection bias, emphasising therefore, 
the need for randomized-controlled trials.  
Assessing the severity of CAD in patients undergoing TAVI 
The optimal treatment of CAD in patients with TAVI remains to be elucidated. While 
Dewey et al.8 showed that CAD is an independent predictor of early and mid-term survival, 
this finding was not further supported by other studies.37, 38, 42, 43 In addition, Khawaja and 
colleagues37 showed that CAD was not predictor of worse outcome; albeit in patients 
exhibiting a SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) score >9. 
More recently, Chauhan and colleagues43 found no significant association between the 
SYNTAX score or Duke Myocardial Jeopardy score with their pre-specified primary 
composite endpoint of all-cause mortality, major adverse cardiovascular and cerebrovascular 
event and postoperative coronary revascularization, nor secondary outcomes of 30-day and 1-
year composite endpoint rates. Moreover, the authors went further and questioned the role of 
coronary angiography as part of the TAVI workup.43  
As previously mentioned, the reported prevalence of CAD in the population undergoing 
TAVI varies depending on the definitions used to define significance (Table I, Supplement), 
and can be as high as 75%.8-12 The severity of CAD in AS patients has historically been 
assessed using angiography to further determine the need for revascularisation. However, it is 
well-known that functionally-guided fractional flow reserve (FFR) PCI strategies have shown 
improvements in patients’ outcome.44 Nonetheless, functional assessment of CAD in the 
presence of AS becomes difficult due to diffuse sub-endocardial ischemia leading to 
myocardial fibrosis, as well as left ventricular remodeling and often severe hypertrophy.45, 46 
Therefore, coronary physiology is altered in patients with severe AS and, although the use of 
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FFR has not been validated for this group, FFR has been safely performed in 
contemporaneous studies of patients with severe AS.47-51 
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Coronary revascularization and TAVI outcomes 
Our meta-analysis suggests that routine revascularization of patients with severe AS 
and concomitant CAD undergoing TAVI may be associated with an increased risk of major 
vascular complications and 30-day mortality, although the latter association was no longer 
present by 1-year. In this regard, Van Mieghem et al.29 have shown no significant difference 
between complete versus incomplete revascularization, but also for SYNTAX scores ≥8 
versus <8. One of the theoretical arguments to support revascularization prior to TAVI is the 
anxiety that peri-procedural MI might occur during the hypotension induced by rapid pacing 
either for valvuloplasty or during valve delivery. Notably, Griese et al.33 showed that 
revascularization was associated with increased 30-day MI compared to TAVI alone. 
However, the study did not ascertain the prevalence of CAD in the TAVI alone group or 
indeed the indication for PCI. As such, this study was excluded from our meta-analysis. 
Singh and colleagues,40 showed worse 30-day outcomes when PCI was performed during the 
same admission, though, as above mentioned, this observation might have been driven by the 
difference in the reported prevalence of CAD between groups, by but also, with a 
questionable definition of CAD using ICD-9 (international classification of diseases, ninth 
revision) coding. The higher 30-day mortality could also be associated with a higher pre-
operative risk profile, meaning that the PCI group may have been a higher-risk cohort, 
translating therefore into worse outcome. However, the authors did not report adjusting for 
pre-procedural risk scoring. Importantly, our analysis shows that when both groups had 100% 
prevalence of CAD, there was no significant difference in treatment effect estimates, likely 
due to a small event rates (Figure 2-A). Moreover, meta-regression analysis suggests that 
differences in the prevalence of CAD did not influence this outcome. Finally, the presence of 
multiple-comorbid conditions contributes explaining overall 30-day mortality, since the 
cardiovascular mortality was similar.  
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Timing for revascularization: concomitant versus a priori approach  
Performing TAVI shortly after PCI mandates the TAVI procedure be performed while 
a patient is treated with dual antiplatelet therapy, potentially increasing bleeding risk. 
However, our analysis shows that major and minor bleeding complications were not 
significantly different between pre-TAVI PCI and isolated TAVI approaches. Studies which 
compared a concomitant to a priori revascularization approach found no significant 
differences for AKI and the need for hemodialysis,10, 23, 33 Interestingly, one would expect 
that the likelihood of AKI increases with a concomitant approach owing to the larger contrast 
volumes and higher number of catheter manipulations; however, as previously reported, 
contrast amount, per-se, was not associated with AKI during TAVI procedures.52 In addition, 
most of the studies that reported the incidence of AKI, the PCI was performed a priori rather 
than in the same setting (one study only), Figures 3 and 4. This finding likely reflects the 
influence of confounding variables as studies were not statistically powered to infer for AKI 
due to the low event rate. 
The revised American guidelines on valvular heart disease have downgraded to Class 
IIa (Evidence C), the role of coronary revascularization at the time of SAVR.3 
Recommendations focused on TAVI13-15 while supporting the treatment of significant CAD, 
do not provide suggestions about the timing of PCI relative to the TAVI procedure. 
Wenaweser et al.,10 reported on a combined approach separated into single-stage and staged 
procedures; later, Van Rosendael et al.36 found no differences when comparing 
revascularisation within 30-day prior to TAVI, with PCI performed ≥30 days after TAVI. 
Thus, there are still very limited data available to inform an optimal strategy with respect to 
timing of the revascularization.    
Limitations 
The present study has several limitations. The main limitation lies with the small 
number of studies, patients and events informing each outcome, and the non-randomized 
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nature of the included studies that introduced selection bias. Importantly, the decision to 
perform PCI as revascularization versus medical management for CAD was at the discretion 
of the heart team and without a consistent selection criteria. In this regard, the decision to 
undertake PCI may relate to unstable symptoms, limiting angina, or patients considered at 
higher-risk. Individual-patient level data was not available, precluding therefore, a more 
robust adjustment for any differences in clinical/anatomical variables or comparisons of 
severity/risk across the cohorts. Finally, one should bear in mind that once TAVI is extended 
to lower-risk younger and less morbid patients, also exhibiting a longer life-expectancy, in 
the case of severe and proximal vessels lesions, it may be beneficial to perform pre-TAVI 
revascularization to prevent potential problematic coronary arteries accessibility in the future. 
The results of the ACTIVATION trial53 will provide further insight into optimal 
revascularization strategies in patients with CAD undergoing TAVI. 
CONCLUSION 
 Our findings suggest that revascularization before or during TAVI confers no clinical 
advantage with respect to several patient-important clinical outcomes, and may be associated 
with an increased risk of major vascular complications and 30-day mortality. These data, 
however, are based on observational studies including initial high-risk cohorts of patients 
with limited follow-up and may not be applicable to lower-risk cohorts with greater life 
expectancy. Randomized-controlled trials are needed to determine the role of routine 
revascularization in patients with significant CAD undergoing TAVI. Meanwhile, in the 
absence of definitive evidence, careful evaluation of patients on an individual basis by a 
dedicated heart team is of paramount importance to identify patients, such as those with 
significant CAD affecting proximal main epicardial vessels, in which the benefits of elective 
revascularization are balanced against the potential risks. 
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Figures legends 
Figure 1. Flow diagram based on the Preferred Reporting Items for Systematic reviews and 
Meta-Analyses (PRISMA). 
 
Figure 2. Meta-analyses evaluating the cumulative risk of A) mortality, B) clinical outcomes 
of patients undergoing transcatheter aortic valve implantation (TAVI) plus percutaneous 
coronary intervention (PCI) versus TAVI alone. AKI: acute kidney injury. M-H: Mantel-
Haenszel. CI: confidence interval.  
 
Figure 3. Sensitivity analysis evaluating the cumulative risk of worse outcomes of patients 
undergoing transcatheter aortic valve implantation (TAVI) plus percutaneous coronary 
intervention (PCI) versus TAVI alone. AKI: acute kidney injury. M-H: Mantel-Haenszel. CI: 
confidence interval. 
 
Figure 4. Meta-analyses evaluating outcomes between concomitant (same-setting) versus a 
priori revascularization of patients undergoing transcatheter aortic valve implantation plus 
percutaneous coronary intervention. M-H: Mantel-Haenszel. CI: confidence interval. 
 
Figure 5. Subgroup analysis according to the percentage in prevalence of significant 
coronary artery disease (CAD) evaluating the cumulative risk of A) 30-day mortality, B) 
cardiovascular mortality, C) 1-year mortality, D) myocardial infarction, E) acute kidney 
injury and/or need for hemodialysis and F) major and life threatening bleeding of patients 
undergoing transcatheter aortic valve implantation (TAVI) plus percutaneous coronary 
intervention (PCI) versus TAVI alone. M-H: Mantel-Haenszel. CI: confidence interval. 
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Table 1: Study design and participant characteristics 
Study ID Design; Country; Year 
No. of participants; 
PCI + TAVI; TAVI 
alone 
Participant inclusion criteria and CAD 
significance definition 
Masson et al. 20109 Retrospective cohort study; Canada; 2005-2007 104; 15; 89 
Patients for TAVI with 
≥50% diameter stenosis in at least one 
coronary artery & DMJS score 
Conradi et al. 201123 Retrospective cohort study; Germany; 2008-2010 28; 28; 0 Patients for TAVI who underwent PCI 
Gautier et al. 201111 Retrospective cohort study; France; 2006-2009 83; 11; 72 
Patients for TAVI with ≥70% epicardial 
coronary artery stenosis or ≥ 50% stenosis of 
left main 
Nowakowski et al. 
201122 
Cohort study; Australia; 
Unclear 70; 15; 55 
Patients for TAVI with no information for 
determination of CAD significance 
Wenaweser et al. 201110 Retrospective cohort study; Switzerland; 2007-2010. 256; 59; 197 
TAVI patient with >50% diameter stenosis in 
at least one coronary artery 
Abdel-Wahab et al. 
201212 
Retrospective cohort study; 
Germany; 2007-2011 125; 55; 70 
TAVI patients with ≥50% stenosis on 
angiography or previous cardiac event 
Bensaid et al. 201224 Cohort study; France; Unclear. 61; 23; 38 TAVI patients with >70% proximal vessel stenosis 
Aktug et al. 201325 Cohort study; Germany; 2008-2012 338; 66; 272  
Patients for TAVI with CAD defined as 
clinically significant 
Arnold et al. 201326 Retrospective cohort study; Germany; Unclear 300; 73; 227 
Patients for TAVI with CAD defined as 
clinically significant 
Codner et al. 201327 Retrospective cohort study; Israel; 2008-2012 153; 36; 117 
Patients for TAVI with CAD defined as 
clinically significant  
Czerwinska-
Jelonkiewicz et al.   
201330 
Retrospective cohort study; 
Poland; 2009-2011 83; 18; 65 Not reported 
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Gasparetto et al. 201328 Retrospective cohort study; Italy; Unclear 152; 39; 113 
Patients for TAVI with ≥50% diameter 
stenosis of at least one epicardial coronary 
artery 
Van Mieghem et al. 
201329 
Retrospective cohort study; 
Netherlands; 2005-2012 138; 39; 99 
Patients for TAVI with >50% diameter 
stenosis in any coronary artery 
Abramowitz et al. 
201431 
Retrospective cohort study; 
Israel; 2009-2012 144; 61; 83 
TAVI patients with >70% stenosis in major 
epicardial coronary artery 
Griese et al. 201433 Retrospective cohort study; Germany; 2009-2012 411; 65; 346 
TAVI patients with CAD significance defined 
as per the institution’s current local practice 
Paradis et al. 201441 Retrospective cohort study; North America; 2007-2012 383; 98; 285 
Patients for TAVI with CAD defined as 
clinically indicated  
Tatar et al. 201432 Retrospective cohort study; France; 2008-2013 141; 38; 103 
Patients for TAVI but no information of 
determination of CAD significance  
Khawaja et al. 201537 Retrospective cohort study; United Kingdom; 2008-2012 93; 25; 68 
Patients for TAVI with epicardial coronary 
artery stenosis ≥70% or left main stem 
stenosis of ≥ 50% 
Mancio et al. 201534 Retrospective cohort study; Portugal; 2007-2012 46; 13; 33 
Patients for TAVI with ≥50% stenosis in 
coronary artery 
Penkalla et al. 201535 Retrospective cohort study; Germany; 2008-2013 308; 76; 232 
>50% stenosis in left main or 
>90% stenosis in LAD, LCx and RCA 
Rosendael et al. 201536 Retrospective cohort study; Netherlands, Unclear 96; 96;0 
TAVI patients with ≥70% stenosis of a 
coronary artery of ≥ 1.5 mm 
Snow et al. 201538 Retrospective cohort study; United Kingdom; 2007-2011 1,339; 172; 1,167 
TAVI patients with >50% stenosis main, 
LAD, LCx and RCA 
Chakravarty et al. 
201639 
Retrospective cohort and 
matched study; International; 
2007-2014 
204 (cohort); 128; 128 Patients with left main PCI from a TAVI-left main registry and matched controls 
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Singh et al. 201640 
Retrospective cohort study 
with propensity matching; 
United States of America; 
2011-2013 
2,349; 588; 1,761 TAVI patients with CAD according to ICD-9 coding 
 
TAVI: transcatheter aortic valve implantation. PCI: percutaneous coronary intervention. CAD: coronary artery disease. DMJS Duke Myocardial Jeopardy score. 
LAD: left anterior descending. LCx: left coronary circumflex. RCA: right coronary artery. ICD-9: international classification of diseases, ninth revision. 
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Table 2: Baseline characteristics for patients who underwent TAVI with and without PCI 
Study ID Strategy Mean Age (years) Male 
Logistic 
EuroSCORE STS score CAD 
Multivessel 
disease LVEF CKD COPD PVD 
Masson et al. 
20109 
TAVI + PCI 
TAVI alone 
85.7 
84.4 
10 (66.6) 
60 (57.8) 
24.5 
31.05 
9.5 
9.7 
15 (100) 
104 (100) N/A 
45.0 
58.4 
0 (0) 
93 (89.4) N/A 
3 (20.0) 
42 (40.3) 
Conradi et al. 
201123 
TAVI + PCI 
TAVI alone 
80.1  
N/A 
13 (46.4)  
N/A 
26.8  
N/A 
9.3  
N/A 
28 (100) 
N/A 
19 (67.9)  
N/A 
45.6  
N/A 
8 (28.6) 
N/A 
7 (25.0)  
N/A 
11 (39.3)  
N/A 
Gautier et al. 
201111 
TAVI + PCI 
TAVI alone 
74±15 
N/A 
9 (81.8) 
N/A 
25±11 
N/A N/A 
11 (100) 
N/A 
7 (63.6) 
N/A 
48±13 
N/A N/A N/A N/A 
Nowakowski 
et al. 201122 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Wenaweser et 
al. 201110 
TAVI + PCI 
TAVI alone 
83.6±4.8 
81.7±6.5 
29 (49.2) 
83 (42.1) 
26.8±16.3 
24.2±14.4 
7.6±6.2 
6.1±4.5 
59 (100) 
108 (54.8) N/A 
51±12 
51±15 N/A N/A 
16 (27.1) 
48 (24.4) 
Abdel-Wahab 
et al. 201212 
TAVI + PCI 
TAVI alone 
81±7.1 
81±6.2 
26 (47.0) 
34 (48.5) 
25.08±12.6 
23.62±15.1 N/A 
55 (100) 
36 (51.4) 
18 (32.7)  
27 (38.6) 
46.9±13.9 
48.5±15.3 N/A N/A 
11 (20.0) 
10 (14.2) 
Bensaid et al. 
201224 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Aktug et al. 
201325 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A 
66 (100) 
155 (57) N/A N/A N/A N/A N/A 
Arnold et al. 
201326 
TAVI + PCI 
TAVI alone 
82±6 
81±6 
39 (54) 
78 (44) N/A N/A N/A N/A N/A N/A N/A N/A 
Codner et al. 
201327 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Czerwinska-
Jelonkiewicz 
et al. 201330 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Gasparetto et 
al. 201328 
TAVI + PCI 
TAVI alone 
N/A  
80.3±6.3 
N/A  
57 (50.4) 
N/A 
23.2±14.1 N/A 
39 (100)  
113 (100) N/A 
N/A 
52.8±12.9 
N/A  
65 (57.5) 
N/A  
25 (22.1) N/A 
Van Mieghem 
et al. 201329 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A 
39 (100) 
99 (100) N/A N/A N/A N/A N/A 
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Abramowitz 
et al. 201431 
TAVI + PCI 
TAVI alone 
83.6±5.5 
83.1±5.1 
33 (50.8)  
40 (48.2) 
31.3±13.8   
29.2±13.8 NA 
61 (100) 
83 (100) 
35 (57.4) 
47 (56.7) 
54.6±9 
55.2±7.5 N/A 
7 (11.5) 
21 (25.3) 
10 (16.4) 
14 (16.9) 
Griese et al. 
201433 
TAVI + PCI 
TAVI alone 
82±6 
82±5 
24 (36.9) 
129 (37.3) 
21.7±13.9 
20.3±14.6 N/A N/A N/A 
52±15 
54±14 
36 (55.3) 
177 (51.2) N/A N/A 
Paradis et al. 
201741 
TAVI + PCI 
TAVI alone N/A 
39 (39.8) 
160 (56.3) N/A N/A 
SYNTAX 
22.0 
18.5 
N/A N/A N/A N/A N/A 
Tatar et al. 
201432 
TAVI + PCI 
TAVI alone 
85±5 
84±6 
18 (47.4) 
54 (52.0) 
31.3±16.6 
31.7±16.8 
7.8±5.8 
7.5±4.7 
38 (100) 
54 (52.4) 
19 (50.0) 
10 (9.7) N/A 
11 (29.0) 
41 (39.8) 
8 (21.1) 
35(34.0) 
8 (21.1) 
41 (39.8) 
Khawaja et al. 
201537 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A 
25 (100) 
68 (100) N/A N/A N/A N/A N/A 
Mancio et al. 
201534 
TAVI + PCI 
TAVI alone N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
Penkalla et al. 
201535 
TAVI + PCI 
TAVI alone 
83 (78-86) 
81 (76-85) 
21 (27.6) 
88 (37.9) 
32.1 (19-52) 
28.5 (18-45) 
11.9 (7-19) 
10.1 (6-19) 
76 (100) 
232 (100) N/A 
55 (40-60) 
50 (41-60) N/A N/A 
50 (65.8) 
160 (69.0) 
Rosendael et 
al. 201536 
TAVI + PCI 
TAVI alone 
81±5.4 
NA 
55 (57.3) 
N/A 
23.2±12.9  
N/A N/A 
96 (100) 
N/A N/A 
54±13 
N/A N/A N/A N/A 
Snow 201538 TAVI + PCI TAVI alone N/A N/A N/A N/A 
172 (100) 
1,167 (100) N/A N/A N/A N/A N/A 
Chakravarty 
201639 
TAVI + PCI 
TAVI alone 
81.7±6.8 
81.0±7.9 
81 (63.3) 
88 (68.7) N/A 
7.8±4.9 
8.0±4.5 
128 (100) 
128 (100) N/A 
53.5±12.4 
55.5±13.6 N/A N/A 
44 (34.4) 
50 (41.4) 
Singh et al. 
201640 
TAVI + PCI 
TAVI alone 
83.0±0.59 
82.9±0.39 
279 (47.4) 
812 (46.1) N/A N/A 
493 (83.9) 
1,125 (63.9) N/A N/A N/A 
164 (27.9) 
560 (31.8) 
189 (32.2) 
526 (29.9) 
 
Data presented as number/sample size (percentage), mean±SD or median (interquartile range). CAD: coronary artery disease. CKD: chronic kidney disease. COPD: chronic 
obstructive pulmonary disease. Log-EuroSCORE: logistic European system for cardiac operative risk evaluation. LVEF: left ventricle ejection fraction (%). Mean gradient 
(mmHg). TAVI: transcatheter aortic valve implantation. PCI: percutaneous coronary intervention. PVD: peripheral vascular disease. STS score: Society of Thoracic Surgeons 
Score for Prediction of Mortality score. N/A: not available. 
  
 32 
Table 3: Newcastle-Ottawa Quality Assessment Scale 
   Selection Bias Comparability Ascertainment and attrition bias Overall Quality 
Study ID 
Sample size 
>50 in each 
arm 
Representativeness 
of exposed cohort 
for TAVI 
population 
Selection of 
non-exposed 
cohort 
Method of 
exposure 
ascertainment 
Outcome 
of interest 
present at 
start? 
Adjustment for 
important 
confounders 
Outcome 
Ascertainment 
(source, criteria) 
Adequate 
length of 
follow-up 
Loss to 
follow-
up 
<10% 
 
Masson et al. 
20109 
No, 15 and 
89 Yes 
All in our 
analysis had 
CAD of varying 
severity 
Pre-operative 
coronary 
angiography 
and Duke 
Myocardial 
Jeopardy Score 
No 
Both groups in our 
analysis had 100% 
CAD, but no other 
adjustments 
Clinical 
appointment follow-
up but adjudication 
not according to 
standardized end-
points 
Yes Yes, unclear Average 
Conradi et al. 
201123 No, 28 Yes All had CAD 
Pre-operative 
coronary 
angiography 
No 
Both groups had 
100% CAD but no 
other adjustments 
Telephone 
interviews but no 
adjudication 
according to 
guidelines 
Yes Yes, none High 
Gautier et al. 
201111 
No, 11 and 
72 Yes All had CAD 
Pre-operative 
coronary 
angiography 
No No adjustment 
Unclear, but 
adjudicated 
according to 
guidelines for 
reporting mortality 
and morbidity in 
TAVI 
Yes Yes, none Average 
Nowakowski 
et al. 201122 
No, 15 and 
55 Yes 
No information 
on CAD 
prevalence 
Unclear Unclear 
No reporting of 
CAD% in each arm 
or other adjustments 
Unclear Unclear. Unclear Low 
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Wenaweser et 
al. 201110 
Yes, 59 and 
197 Yes 
Dissimilar CAD 
distribution 
between 
exposed and 
non-exposed 
cohorts 
Pre-procedural 
left heart 
catheterization 
No 
No adjustments, 
imbalance in CAD 
between arms 
Data from 
municipal civil 
registries and 
hospital records. 
Data recorded in 
accordance with 
VARC guidelines, 
but which version is 
unclear 
Yes Yes, none Average 
Abdel-Wahab 
et al. 2012 12 
Yes, 55 and 
70 Yes 
Non-exposed 
cohort had 
different rate of 
CAD 
Pre-operative 
coronary 
angiography 
No No, not controlling for CAD 
No information on 
source employed. 
Outcomes 
adjudicated in 
accordance with 
VARC-1 guidelines 
Yes 
Yes, 
0.8% 
loss to 
follow 
up 
Average 
Bensaid et al. 
201224 
No, 23 and 
38 Yes 
No information 
on CAD 
prevalence 
Pre-operative 
coronary 
angiography 
Unclear 
CAD % same in 
both groups but no 
other adjustments 
Unclear source and 
adjudication 
guidelines 
Yes Unclear Low 
Aktug et al. 
201325 
Yes, 66 and 
272 Yes 
Dissimilar CAD 
distribution 
between 
exposed and 
non-exposed 
cohorts 
Unclear No 
No, not controlling 
for CAD or other 
factors 
Unclear source and 
adjudication 
guidelines 
Yes Unclear Low 
Arnold et al. 
201326 
Yes, 73 and 
227 Yes 
No information 
on CAD 
prevalence 
Unclear Unclear 
No, not controlling 
for CAD or other 
factors 
Unclear Yes Unclear Low 
Codner et al. 
201327 
No, 36 and 
117 Yes 
No separate 
information on 
CAD 
prevalence 
Pre-operative 
coronary 
angiography 
No No adjustments 
Participants 
prospectively 
examined. Data 
recorded in 
accordance with 
VARC-1 criteria 
Yes Yes, none Average 
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Czerwinska-
Jelonkiewicz 
et al. 2013 30 
No, 18 and 
65 Yes 
No information 
on CAD 
prevalence 
Unclear No No adjustments 
Telephone 
interviews. Data 
recorded in 
accordance with 
VARC-1 criteria 
Yes 
Yes, 
2.4% 
loss to 
follow 
up 
Low 
Gasparetto et 
al. 201328 
No, 39 and 
113 Yes All had CAD 
Pre-operative 
coronary 
angiography or 
history 
No No adjustments 
Unclear. Data 
recorded in 
accordance with 
VARC-1 criteria 
Yes Yes, none. Average 
Van Mieghem 
et al. 201329 
No, 39 and 
99 Yes Unclear 
Pre-operative 
coronary 
angiography 
No No adjustments Clinical follow-up. VARC-1 criteria Yes 
Yes, 
none Average 
Abramowitz 
et al. 2014 31 
Yes, 61 and 
83 Yes 
Non-exposed 
cohort similar to 
exposed in 
terms of CAD 
Pre-procedural 
coronary 
angiography 
No Yes, controlling for CAD 
Outcomes 
prospectively 
recorded in clinical 
assessments 
employing VARC-1 
guidelines 
Yes Yes, none High 
Griese et al. 
201433 
Yes 65 and 
346 Yes 
No information 
on CAD 
prevalence 
Pre-operative 
cardiac 
catheterisation 
No No adjustment and CAD % unreported 
Yes, Phone calls. 
Data recorded in 
accordance with 
VARC-2 criteria 
Yes 
Yes, 
100% 
follow 
up 
Average 
Paradis et al. 
201741 
Yes, 98 and 
285 Yes 
No information 
on CAD 
prevalence 
Pre-TAVI 
coronary 
angiogram 
Unclear 
Multivariate 
analysis for 
mortality but not for 
other outcomes.  
Not data on 
variables included 
in the model 
Adjudicated 
outcomes according 
to VARC-1 
definition by 
clinical event 
committee 
Yes Unclear Average 
Tatar et al. 
201432 
Yes, 38 and 
103 Yes 
Non-exposed 
cohort had 
different rate of 
CAD 
Unclear No 
No adjustments, 
imbalance in CAD 
between arms 
Unclear Yes Yes, none Low 
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Khawaja et al. 
201537 
No, 25 and 
68 Yes 
All patients in 
analysed sub-
group had CAD 
Pre-TAVI 
coronary 
angiogram and 
SYNTAX score 
calculation 
No 
In the subgroup 
analysis all patients 
had CAD, but no 
other adjustments 
Database, with 
outcomes reported 
according to 
VARC-2 criteria 
Yes Yes, none High 
Mancio et al.  
201534 
No, 13 and 
33 Yes All had CAD 
Pre-procedural 
coronary 
angiography 
No 
100% CAD in both 
groups, no other 
adjustments 
Unclear Yes Yes, none High 
Penkalla et al. 
201535 
Yes, 76 and 
232 Yes 
Information on 
CAD present 
and stratified 
according to 
significance 
Pre-TAVI 
coronary 
angiogram and 
SYNTAX score 
calculation 
No 
Adjusted for 
comparison between 
group II and III as 
they all had CAD, 
no other 
adjustments 
Mortality 
ascertained from 
German Register of 
Residents and 
clinical outcomes 
from prospective e-
database. 
Ascertainment 
according to 
VARC-2 consensus 
guidelines 
Yes Unclear High 
Rosendael et 
al. 201536 No, 96 Yes All had CAD 
Pre-operative 
coronary 
angiograms 
with SYNTAX 
score 
calculation 
No No adjustments 
Electronic record 
keeping, using 
VARC-2 criteria 
Yes Yes, none Average 
Snow et al. 
201538 
Yes, 172 
and 2,416 Yes 
Unequal CAD 
distribution 
between 
exposed and 
non-exposed 
Pre-TAVI 
coronary 
angiogram 
No No adjustments 
Prospectively 
entered data from 
electronic BCIS and 
SCTS database. 
Data linked to the 
Office of National 
Statistics and 
National Records of 
Scotland 
Yes Unclear Average 
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Chakravarty 
et al. 2016 39 
Yes, 128 
and 128 Yes 
No information 
on CAD 
prevalence but 
matched for 
unprotected left 
main stem 
Pre-operative 
coronary 
angiography 
and CT scans 
No Matched control subjects 
Data from registry, 
recorded in 
accordance with 
VARC-2 guidelines 
Yes Yes, none High 
Singh et al. 
201640 
Yes, 588 
and 1,761 Yes 
Unequal CAD 
distribution 
between the two 
groups 
No information 
on how 
significance was 
determined 
Unclear 
Propensity matching 
for some 
confounders but not 
for CAD 
Outcomes 
ascertained via the 
Nationwide 
Inpatient sample. 
ICD-9 codes used 
Unclear Yes, none Average 
 
BCIS: British Cardiovascular Intervention Society. CAD: coronary artery disease. ICD-9: International Classification Disease-9. SCTS: Society of Cardiothoracic Surgeons. 
TAVI: trans-catheter aortic valve implantation. VARC: Valve academic research consortium.  
 
  
 37 
Table 4: Procedural-related complications and follow-up clinical outcome 
Author, Year Type of Valve Approach Timing of PCI Outcomes TAVI + PCI TAVI alone 
Masson et al. 20109 
Edwards- SAPIEN 
(100%) 
Transfemoral: 82/119 
(69%) 
a priori 
Median 26 days 
range 3-100 days 
30-day mortality 0/15 (0) 12/89 (14) 
1-year mortality 3/15 (20) 26/89 (29) 
Conradi et al. 201123 
Medtronic CoreValve 
Edwards SAPIEN 
Transapical: 17/28 (61%) 
Transfemoral: 11/28 
(39%) 
Concomitant and 
a priori up to 4 weeks 
before TAVI 
 Concomitant a priori  
Procedural & 30-day 
mortality 2/7 (29) 0/21 (0) 
N/A AKI 2/7 (29) 0/21(0) 
Non-severe bleeding 0/7 (0) 2/21 (10) 
Gautier et al. 201111 
Medtronic CoreValve 
Edwards SAPIEN 
Transfemoral 
Trans-subclavian 
Concomitant and 
a priori, mean delay 
6±6 weeks 
30-day mortality 8/83 (9.6) 
Stroke 2/83 (2.4) 
MI 8/83 (9.6) 
Severe bleeding 5/83 (6.0) 
Vascular complications 9/83 (11) 
Nowakowski et al. 
201122 N/A 
Concomitant and 
a priori, at least 6 
weeks prior to TAVI in 
all but 6 patients 
 Concomitant a priori 
N/A Stroke 0/6 (0) 1/9 (11.1) 
AKI 0/6 (0) 2/9 (22) 
Vascular complications 1/6 (17) 0/9 (0) 
Wenaweser et al. 
201110 
Medtronic CoreValve 
Edwards SAPIEN 
Transfemoral 
Trans-subclavian 
Transapical 
Concomitant and 
a priori 
 Concomitant a priori  
30-day mortality 4/36 (11) 2/23 (8.7) 11/197 (5.6) 
30-day cardiovascular 
mortality 3/59 (5.1) 0/9 (0) 
30-day stroke 2/36 (5.6) 0/23 (0) 8/197 (4.1) 
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30-day MI 0/36 (0) 0/23 (0) 1/197 (0.5) 
Life threatening 
bleeding 2/36 (5.6) 3/23 (13) 24/197 (12) 
Major bleeding 21/59 (36) 57/197 (29) 
Major access site 
related complication 1/36 (2.8) 3/23 (13) 12/197 (6.1) 
Minor access site 
related complication 5/59 (8.5) 18/197 (9.1) 
Combined safety end-
point 8/36 (22) 6/36 (17) 61/197 (31) 
AKI (I, II & III) 8/59 (14) 35/197 (18) 
Permanent pacemaker 
implantation 14/59 (24) 46/197 (23) 
Abdel-Wahab et al. 
2012 12 
Medtronic CoreValve 
Transfemoral: 124/125 
(99.2%) 
Trans-subclavian: 1/125 
(0.8%) 
a priori 
Median 10 days 
range 0 to 90 days 
30-day mortality 1/55 (1.8) 4/70 (5.7) 
30-day cardiovascular 
mortality 1/55 (1.8) 3/70 (4.3) 
30-day stroke 1/55 (1.8) 4/70 (5.7) 
30-day life threatening 
bleeding 4/55 (7.3) 4/70 (5.7) 
30-day major bleeding 6/55 (11) 8/70 (11) 
30-day minor bleeding 4/55 (7.3) 3/70 (4.3) 
30-day major vascular 
complications 3/55 (5.5) 2/70 (2.9) 
30-day minor vascular 
complications 8/55 (15) 10/70 (14) 
30-day combined safety 
end-point 6/55 (11) 9/70 (13) 
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30-day permanent 
pacemaker 16/55 (30) 11/70 (16) 
30-day hemodialysis 0/55 (0) 2/70 (2.9) 
6-month mortality 4/48 (8.3) 8/59 (14) 
6-month coronary 
events 2/48 (4.2) 0/59 (0) 
6-month stroke 2/48 (4.2) 3/59 (5.1) 
6-month bleeding 10/48 (21) 13/59 (22) 
6-month permanent 
pacemaker 16/48 (33) 11/59 (19) 
6-month hemodialysis 0/48 (0) 1/59 (1.7) 
Bensaid et al. 201224 Medtronic CoreValve 
a priori 
One month prior to 
TAVI 
Composite of heart 
failure, MI and 
mortality 
6/23 (26) 12/38 (32) 
Aktug et al. 201325 
Medtronic CoreValve: 
183/338 (54.1%) 
Edwards SAPIEN: 
146/338 (43.2%) 
Symetis Acurate: 9/338 
(2.7%) 
Concomitant and 
a priori 
Mean 13±9 days 
30-day mortality 8/66 (12) 27/272 (9.9) 
Arnold et al. 201326 
Balloon-expandable valve 
Transapical: 200/300 
(66.7%) 
Transfemoral: 100/300 
(33.3%) 
N/A 
30-day mortality 8/73 (11) 26/227 (12) 
Long-term mortality 25/73 (34) 59/227 (26) 
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Codner et al. 201327 
Medtronic CoreValve 
Edwards-SAPIEN       
Transfemoral: 112/153 
(73.2%)          
Transapical: 27/153 
(17.6%)          
Transaxillary: 13/153 
(8.5%)              
Transaortic: 1/153 (0.6%) 
Concomitant and 
a priori 1-year mortality 5/36 (14) 8/117 (6.8) 
Czerwinska-
Jelonkiewicz et al. 
201330 
Medtronic CoreValve   
Edwards 
SAPIEN/SAPIEN-XT 
Transfemoral 59/83 
(71%) 
Trans-subclavian 8/83 
(9.6%)             
Transapical 16/83 
(19.2%) 
N/A Bleeding complications 17/18 (94) 34/65 (52) 
Gasparetto et al. 
201328 
Medtronic CoreValve 
Edwards 
SAPIEN/SAPIEN-XT 
Transfemoral 
Trans-subclavian 
a priori, median 27 
(IQR 8-51) days 
30-day mortality N/A 5/113 (4.4) 
30-day cardiovascular 
mortality N/A 6/113 (5.3) 
30-day stroke N/A 3/113 (2.7) 
30-day MI N/A 5/113 (4.4) 
30-day life threatening 
bleeding N/A 4/113 (3.5) 
30-day major vascular 
complications N/A 7/113 (6.2) 
30-day combined safety 
end-point N/A 12/113 (11) 
30-day AKI (Stage III) N/A 6/113 (5.3) 
 41 
1-year mortality N/A 16/106 (15) 
1-year cardiovascular 
mortality N/A 4/106 (3.8) 
1-year major stroke N/A 1/106 (0.9) 
1-year MI N/A 2/106 (1.9) 
1-year major bleeding N/A 1/106 (0.94) 
Van Mieghem et al. 
201329 
Medtronic CoreValve 
Edwards SAPIEN 
Transfemoral 
Transaxillary, Transapical 
Concomitant and 
a priori 
 
N/A N/A N/A 
Abramowitz et al. 
201431 
Medtronic CoreValve 
Edwards SAPIEN 
Transfemoral 
Trans-subclavian 
a priori 
Mean 56.5±29.4 days 
30-day mortality 1/61(1.6) 2/83 (2.4) 
30-day stroke 2/61 (3.3) 2/83 (2.4) 
30-day MI 0/61 (0) 0/83 (0) 
30-day major bleeding 2/61 (3.3) 1/83 (1.2) 
30-day major vascular 
complications 3/61 (4.9) 2/83 (2.4) 
30-day minor vascular 
complications 9/61 (15) 4/83 (4.8) 
30-day combined safety 
end-point 5/61 (8.2) 5/83 (6.0) 
30-day permanent 
pacemaker 13/61 (21.3) 22/83 (26.5) 
30-day hemodialysis 0/61 (0) 0/83 (0) 
Griese et al. 201433 
Medtronic CoreValve 
Edwards SAPIEN-XT 
Symetis Acurate 
Transfemoral: 190/411 
(46.2%) 
Transapical: 221/411 
Concomitant and         
a priori, 36±38 days 
 
 Concomitant a priori  
30-day mortality 3/17 (18) 7/48 (15) 18/346 (5.2) 
30-day cardiovascular 
mortality 3/17 (18) 7/48 (15) 18/346 (5.2) 
30-day stroke 0/17 (0) 0/48 (0) 6/346 (1.7) 
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(53.8%) 30-day MI 2/17 (12) 2/48 (4.2) 3/346 (0.9) 
30-day major bleeding 3/17 (17) 7/48 (15) 93/346 (27) 
30-day major vascular 
complications 0/10 (0) 1/23 (4.4) 8/157 (5.1) 
30-day permanent 
pacemaker 0/17 (0) 0/48 (0) 76/346 (22) 
30-day Stage III AKI 1/17 (5.9) 2/48 (4.2) 20/346 (5.8) 
Paradis et al. 201441 
Edwards SAPIEN 
Transfemoral: 200/383 
(52.2%) 
Transapical: 183/383 
(47.8%) 
a priori 
Up to 6 months before 
TAVI 
30-day mortality 4/98 (4.1) 27/285 (9.5) 
Major bleeding 
complications 6/98 (6.1) 21/285 (7.4) 
Major vascular 
complications 3/98 (3.1) 22/285 (7.7) 
AKI stage III 1/98 (1.0) 3/285 (1.1) 
1-year mortality 10/98 (10) 69/285 (24) 
Tatar et al. 201432 
Medtronic CoreValve: 
8/141 (5.7%) 
Edwards SAPIEN: 
126/141 (89.4%) 
St. Jude Portico: 7/141 
(4.96%) 
Transfemoral: 141/141 
(100%) 
 
In hospital mortality 2/38 (5.3) 2/103 (1.9) 
Cardiovascular 
mortality 1/38 (2.6) 1/103 (1.0) 
Stroke 2/38 (5.3) 1/103 (1.9) 
Myocardial infarction 0/38 (0) 0/103 (0) 
Life threatening 
bleeding 0/38 (0) 2/103 (1.9) 
Major bleeding 0/38 (0) 1/103 (1.0) 
Minor bleeding 0/38 (0) 0/103 (0) 
Major vascular 
complications 1/38 (2.6) 3/103 (2.9) 
Minor vascular 
complications 0/38 (0) 2/103 (1.9) 
New Pacemaker 2/38 (5.3) 10/103 (9.7) 
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AKI stage I, II & III 13/38 (34) 17/103 (17) 
1-year mortality 11/38 (29) 21/103 (20) 
2-year mortality 13/38 (34) 48/103 (47) 
Khawaja et al. 201537 
Edwards SAPIEN 
Transfemoral 47/93 
(50.5%) 
Transapical: 29/93 
(31.2%) 
Trans-aortic: 17/93 
(18.3%) 
a priori 
Median 49.5 (IQR 25-
127) days 
30-day mortality 2/25 (8) 5/68 (7.4) 
1-year mortality 6/25 (24) 15/68 (22) 
Mancio et al. 201534 
Medtronic CoreValve 
Edwards SAPIEN 
Transfemoral 
Transapical 
Trans-subclavian 
Concomitant (2/13) 
and a priori (11/13) 
Median 56 (IQR 3-166)  
days 
30-day mortality 2/13 (15) 4/33 (12) 
30-day stroke 1/13 (7.7) 1/33 (3.0) 
30-day life threatening 
bleeding 2/13 (15) 10/33 (30) 
30-day major vascular 
complications 2/13 (15) 11/33 (33) 
30-day AKI 4/13 (31) 10/33 (30) 
30-day permanent 
pacemaker 3/13 (23) 13/33 (39) 
Penkalla et al. 201535 Edwards SAPIEN (100%) Transapical (100%) Concomitant 
30-day mortality 2/76 (2.6) 9/232 (3.9) 
Peri and post 
procedural MI 1/76 (1.3) 4/232 (1.7) 
AKI stage I & III 16/76 (21) 43/232 (19) 
1-year mortality 30/76 (40) 94/232 (41) 
2-year mortality 46/76 (61) 151/232 (65) 
3-year mortality 63/76 (83) 188/232 (81) 
4-year mortality 73/76 (96) 221/232 (95) 
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van Rosendael et al. 
201536 
Medtronic CoreValve 
Edwards SAPIEN    
Transfemoral 
Transapical 
A priori 
 a priori 
≥30 days 
a priori 
<30 days  
In-hospital death 4/48 (8.3) 2/48 (4.2) 
N/A 
30-day stroke 1/48 (2.1) 1/48 (2.1) 
30-day major bleeding 4/48 (8.3) 4/48 (8.3) 
30-day minor bleeding 0/48 (0) 6/48 (13) 
30-day major vascular 
injury 3/48 (7.3) 5/48 (10) 
30-day minor vascular 
injury 1/48 (2.1) 8/48 (17) 
30-day combined safety 
endpoint 9/48 (19) 6/48 (13) 
30-day AKI 8/48 (17) 8/48 (17) 
30-day Atrioventricular 
block 7/48 (7.3) 2/48 (4.2) 
Snow et al. 201538 NA Concomitant and a priori 1-year mortality 36/172 (21) 246/1,167 (21) 
Chakravarty et al. 
201639 
Medtronic CoreValve 
Edwards SAPIEN 
Direct Flow 
Transfemoral/Trans-
subclavian: 194/256 
(75.8%) 
Alternative Access: 
44/256 (17.2%) 
Concomitant and 
a priori 
30-day mortality 4/128 (3.1) 3/128 (2.3) 
30-day stroke 1/128 (0.8) 2/128 (1.6) 
30-day MI 0/128 (0) 0/128 (0) 
Procedural death 0/128 (0) 1/128 (0) 
Procedural major or life 
threatening bleeding 22/128 (17) 33/128 (26) 
Procedural major 
vascular complications 21/128 (16) 5/128 (3.9) 
Permanent pacemaker 34/128 (27) 18/128 (14) 
AKI 6/128 (4.7) 7/128 (5.5) 
1-year mortality 12/128 (9.4) 13/128 (10) 
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1-year stroke 1/128 (0.8) 3/128 (2.3) 
1-year MI 3/128 (2.3) 1/128 (0.8) 
Singh et al. 201640 
Transfemoral/transaortic 
(84.6%) 
Transapical (15.4%) 
Concomitant and 
a priori 
In-hospital mortality 60/588 (10) 120/1,761 (6.8) 
In-hospital neurological 
complications 20/588 (3.4) 128/1,761 (7.3) 
In-hospital bleeding 
requiring transfusion 45/588 (7.7) 217/1,761 (12) 
In-hospital major 
vascular complications 50/588 (8.5) 79/1,761 (4.5) 
In-hospital AKI 
requiring dialysis 5/588 (0.9) 44/1,761 (2.5) 
In-hospital permanent 
pacemaker 34/588 (5.8) 190/1,761 (11) 
 
Data presented as the occurrence of an event/sample size (percentage). AKI: acute kidney injury. IQR: Interquartile range. MI: myocardial infarction. PCI: percutaneous 
coronary intervention. TAVI: Transcatheter Aortic Valve Implantation.  
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Table 5. Pooled analysis for adverse outcomes with and without revascularization 
Outcome Studies Cumulative % References Studies TAVI PCI % References Studies 
TAVI 
alone % References 
30-day Mortality 18 401/5,574 7.2% 
9-12, 23, 25, 26, 
28, 29, 31-37, 39-
41 
16 118/1,484 7.95% 
9, 10, 12, 23, 25, 
26, 29, 31-37, 39-
41 
16 275/4,007 6.9% 
9-12, 25-29, 31-35, 
37, 39-41 
30-day cardiovascular 
mortality 5 52/1,046 5.0% 
10, 12, 28, 31, 32 4 15/217 6.9% 10, 12, 31, 32 5 37/829 4.5% 10, 12, 28, 31, 32 
1-year Mortality 9 607/2,883 21% 
9, 27, 28, 32, 35, 
37-39, 41 8 113/588 19.2% 
9, 27, 32, 35, 37-
39, 41 9 494/2,295 21.5% 
9, 27, 28, 32, 35, 
37-39, 41 
2-year Mortality 2 258/449 57.5% 32, 35 2 59/114 51.8% 32, 35 2 199/335 59.4% 32, 35 
Myocardial infarction 10 33/1,903 1.7% 
10-12, 25, 28, 31-
33, 35, 39 8 12/548 2.2% 
10, 12, 25, 31-33, 
35, 39 8 13/1,272 1.02% 
10, 12, 28, 31-33, 
35, 39 
Major or life-
threatening bleeding 13 608/4,403 13.8% 
10-12, 28, 31-36, 
39-41 10 140/1,201 11.6% 
10, 12, 31-34, 36, 
39-41 10 463/3,119 14.8% 
10, 12, 28, 31-34, 
39-41 
Major vascular 
complications 11 247/4,099 6.02% 
10, 12, 28, 31-34, 
36, 39-41 10 96/1,169 8.2% 
10, 12, 31-34, 36, 
39-41 10 151/2,930 5.2% 
10, 12, 28, 31-34, 
39-41 
Acute kidney injury 14 263/4,671 5.6% 
10, 12, 22, 23, 28, 
31-36, 39-41 13 76/1,320 5.8% 
10, 12, 22, 23, 31-
36, 39-41 11 187/3,351 5.6% 
10, 12, 28, 31-35, 
39-41 
Stroke/transient 
ischemic attack 12 43/1,752 2.45% 
10-12, 22, 25, 28, 
31-34, 36, 39 10 14/596 2.3% 
10, 12, 22, 25, 31-
34, 36, 39 8 27/1,073 2.5% 
10, 12, 28, 31-34, 
39 
Pacemaker 
implantation 8 519/3,728 13.9% 
10, 12, 31-34, 39, 
40 8 133/1,007 13.2% 
10, 12, 31-34, 39, 
40 8 386/2,721 14.2% 
10, 12, 31-34, 39, 
40 
 
TAVI: transcatheter aortic valve implantation. PCI: percutaneous coronary intervention. Values are expressed as the occurrence of an event/sample size. 
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Table 6: Sensitivity Analysis for Clinical Outcomes Comparing the Percentage of Reported Coronary Artery 
Disease in Studies Without Revascularization 
 
Outcome 
Random effects 
odds ratio 
[95%CI] 
Fixed effects 
odds ratio 
[95%CI] 
Random effects 
odds ratio 
excluding studies 
with no events in 
at least one arm 
30-day mortality 1.39 [1.08-1.79] 1.34 [1.04-1.71] 1.41 [1.10-1.81] 
  100% CAD in TAVI alone group 0.82 [0.30-2.20] 0.80 [0.30-2.16] 0.82 [0.30-2.20] 
  >50% CAD in TAVI alone group 1.44 [1.11-1.87] 1.39 [1.08-1.80] 1.47 [1.13-1.90] 
1-year mortality 1.03 [0.79-1.34] 1.03 [0.79-1.33] 1.03 [0.79-1.34] 
  100% CAD in TAVI alone group 0.99 [0.73-1.33] 0.99 [0.74-1.34] 0.99 [0.73-1.33] 
  >50% CAD in TAVI alone group 1.12 [0.57-2.20] 1.13 [0.66-1.93] 1.12 [0.57-2.20] 
Cardiovascular mortality 1.03 [0.37-2.87] 0.98 [0.36-2.65] 1.03 [0.37-2.87] 
  >50% CAD in TAVI alone group 1.03 [0.37-2.87] 0.98 [0.36-2.65] 1.03 [0.37-2.87] 
Myocardial infarction 0.86 [0.14-5.17] 0.85 [0.14-5.11] 0.76 [0.09-6.72] 
  100% CAD in TAVI alone group 0.76 [0.09-6.72] 0.76 [0.09-6.72] 0.76 [0.09-6.72] 
  >50% CAD in TAVI alone group 1.10 [0.05-26.65] 1.10 [0.05-26.65] Not estimable 
Major or life threatening bleeding 0.87 [0.58-1.29] 0.76 [0.61-0.95] 0.89 [0.58-1.35] 
  100% CAD in TAVI alone group 2.72 [0.25-29.33] 2.72 [0.25-29.33] 2.72 [0.25-29.33] 
  >50% CAD in TAVI alone group 0.84 [0.56-1.26] 0.75 [0.60-0.94] 0.86 [0.55-1.32] 
Major vascular or access site 
complication 1.79 [1.31-2.45] 1.78 [1.31-2.43] 1.79 [1.31-2.45] 
  100% CAD in TAVI alone group 2.04 [0.35-11.84] 2.04 [0.35-11.84] 2.04 [0.35-11.84] 
  >50% CAD in TAVI alone group 1.79 [1.30-2.45] 1.77 [1.29-2.43] 1.79 [1.30-2.45] 
Acute kidney injury and/or dialysis 0.89 [0.47-1.71] 0.90 [0.65-1.23] 0.94 [0.48-1.84] 
  100% CAD in TAVI alone group 1.14 [0.68-1.90] 1.14 [0.68-1.90] 1.14 [0.68-1.90] 
  >50% CAD in TAVI alone group 0.77 [0.29-2.06] 0.79 [0.53-1.19] 0.85 [0.29-2.43] 
Stroke 1.06 [0.39-2.86] 1.00 [0.42-2.40] 1.06 [0.39-2.86] 
  100% CAD in TAVI alone group 1.36 [0.20-9.39] 1.36 [0.20-9.39] 1.36 [0.20-9.39] 
  >50% CAD in TAVI alone group 1.02 [0.25-4.21] 0.92 [0.34-2.46] 1.02 [0.25-4.21] 
Pacemaker implantation 0.87 [0.54-1.39] 0.72 [0.57-0.92] 0.87 [0.54-1.39] 
  100% CAD in TAVI alone group 0.80 [0.44-1.47] 0.80 [0.44-1.47] 0.80 [0.44-1.47] 
  >50% CAD in TAVI alone group 0.89 [0.48-1.66] 0.71 [0.55-0.92] 0.89 [0.48-1.66] 
Combined safety 0.84 [0.55-1.27] 0.84 [0.56-1.28] 0.84 [0.55-1.27] 
  100% CAD in TAVI alone group 1.36 [0.41-4.49] 1.36 [0.41-4.49] 1.36 [0.41-4.49] 
  >50% CAD in TAVI alone group 0.78 [0.50-1.22] 0.78 [0.50-1.23] 0.78 [0.50-1.22] 
 
CI: confidence interval. TAVI: transcatheter aortic valve implantation. CAD: coronary artery disease. 
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Table 7: Meta-regression Examining the Influence of Coronary Artery Disease on Outcomes 
 
Outcome Exp(b) (95%CI) P-value 
30-day mortality 0.98 (0.94-1.02) 0.23 
1-year mortality 0.99 (0.94-1.04) 0.36 
Cardiovascular mortality 0.92 (0.15-5.71) 0.68 
Myocardial infarction insufficient observations - 
Major or life threatening 
bleeding 1.05 (0.99-1.10) 0.074 
Major vascular or access 
site complication 0.99 (0.91-1.07) 0.72 
Acute kidney injury or 
hemodialysis 1.01 (0.90-1.13) 0.77 
Stroke 0.98 (0.74-1.31) 0.81 
Permanent pacemaker 1.01 (0.94-1.09) 0.64 
Combined safety 1.03 (0.65-1.64) 0.57 
 
CI: confidence interval. 
 
